Synergistic interaction between sorafenib and gemcitabine in EGFR‑TKI‑sensitive and EGFR‑TKI‑resistant human lung cancer cell lines

Li,Jing; Pan,Yue‑Yin; Zhang,Ying

doi:10.3892/ol.2012.1017

Synergistic interaction between sorafenib and gemcitabine in EGFR‑TKI‑sensitive and EGFR‑TKI‑resistant human lung cancer cell lines

Authors:
- Jing Li
- Yue‑Yin Pan
- Ying Zhang
View Affiliations

Affiliations: Department of Geriatrics, The Third Affiliated Hospital of Anhui Medical University, Hefei 230061, P.R. China, Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, P.R. China
Published online on: November 7, 2012 https://doi.org/10.3892/ol.2012.1017
Pages: 440-446

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Sorafenib is a highly selective multi‑targeted agent and has been reported to have potent antitumor effects against various tumors, including human non‑small cell lung cancer (NSCLC). In the present study, we explored the antitumor effect and associated molecular mechanisms of sorafenib against human lung cancer cell lines in vitro. We also investigated the efficacy of concurrent and sequential administration of sorafenib and gemcitabine in epidermal growth factor receptor (EGFR)‑tyrosine kinase inhibitor (TKI)‑sensitive and EGFR‑TKI‑resistant NSCLC cell lines. The PC‑9 (EGFR‑TKI‑sensitive, EGFR-mutated) and A549 (EGFR‑TKI‑resistant, K‑Ras-mutated) NSCLC cell lines were treated with sorafenib and gemcitabine, alone, in combination or with different schedules. Cytotoxicity was assessed by MTT assay, cell cycle distribution was analyzed by flow cytometry and alterations in signaling pathways were analyzed by western blotting. We found that sorafenib exhibited dose‑dependent growth inhibition in the EGFR‑TKI‑sensitive and EGFR-TKI‑resistant NSCLC cell lines, and the sequence gemcitabine→sorafenib exhibited the strongest synergism. Sorafenib arrested the cell cycle at G1 phase, whereas gemcitabine caused arrest at S phase. The molecular mechanism of this synergism is that the downstream signaling pathways that were initially activated by gemcitabine exposure were efficiently suppressed by the subsequent exposure to sorafenib. By contrast, the reverse of this sequential administration resulted in antagonism, which may be due to differential effects on cell cycle arrest. The results suggest that sorafenib as a single agent exhibits anti‑proliferative effects in vitro in NSCLC cell lines with EGFR and K‑Ras mutations and that the sequential administration of gemcitabine followed by sorafenib is superior to sorafenib followed by gemcitabine and concurrent administration.

View Figures

View References

1.	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
2.	Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
3.	Maemondo M, Inoue A, Kobayashi K, et al: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
4.	Masago K, Fujita S, Togashi Y, et al: Clinicopathologic factors affecting the progression-free survival of patients with advanced non-small-cell lung cancer after gefitinib therapy. Clin Lung Cancer. 12:56–61. 2011. View Article : Google Scholar : PubMed/NCBI
5.	Pao W, Wang TY, Riely GJ, et al: KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2:e172005. View Article : Google Scholar : PubMed/NCBI
6.	Gazdar AF: Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene. 28:S24–S31. 2009. View Article : Google Scholar : PubMed/NCBI
7.	Rodenhuis S, Slebos RJ, Boot AJ, et al: Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. Cancer Res. 48:5738–5741. 1988.PubMed/NCBI
8.	Mitsudomi T, Kosaka T, Endoh H, et al: Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol. 23:2513–2520. 2005. View Article : Google Scholar
9.	Kosaka T, Yatabe Y, Endoh H, et al: Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res. 12:5764–5769. 2006. View Article : Google Scholar : PubMed/NCBI
10.	Toi M, Matsumoto T and Bando H: Vascular endothelial growth factor:its prognostic, predictive, and therapeutic implications. Lancet Oncol. 2:667–673. 2001. View Article : Google Scholar : PubMed/NCBI
11.	Alvarez RH, Kantarjian HM and Cortes JE: Biology of platelet-derived growth factor and its involvement in disease. Mayo Clinic Proceedings. 81:1241–1257. 2006. View Article : Google Scholar : PubMed/NCBI
12.	Ferrara N, Gerber HP and LeCouter J: The biology of VEGF and its receptors. Nat Med. 9:669–676. 2003. View Article : Google Scholar : PubMed/NCBI
13.	Wu E, Palmer N, Tian Z, et al: Comprehensive dissection of PDGF-PDGFR signaling pathways in PDGFR genetically defined cells. PLoS One. 3:e37942008. View Article : Google Scholar : PubMed/NCBI
14.	Erber R, Thurnher A, Katsen AD, et al: Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J. 18:338–340. 2004.PubMed/NCBI
15.	Shikada Y, Yonemitsu Y, Koga T, et al: Platelet-derived growth factor-AA is an essential and autocrine regulator of vascular endothelial growth factor expression in non-small cell lung carcinomas. Cancer Res. 65:7241–7248. 2005. View Article : Google Scholar
16.	Donnem T, Al-Saad S, Al-Shibli K, Busund LT and Bremnes RM: Co-expression of PDGF-B and VEGFR-3 strongly correlates with lymph node metastasis and poor survival in non-small-cell lung cancer. Ann Oncol. 21:223–231. 2010. View Article : Google Scholar : PubMed/NCBI
17.	Linardou H, Dahabreh IJ, Kanaloupiti D, et al: Assessment of somatic k-Ras mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small cell lung cancer and colorectal cancer. Lancet Oncol. 9:962–972. 2008. View Article : Google Scholar : PubMed/NCBI
18.	Rodenhuis S, van de Wetering ML, Mooi WJ, Evers SG, van Zandwijk N and Bos JL: Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. N Engl J Med. 317:929–935. 1987. View Article : Google Scholar : PubMed/NCBI
19.	Lopez-Chavez A, Carter CA and Giaccone G: The role of KRAS mutations in resistance to EGFR inhibition in the treatment of cancer. Curr Opin Investig Drugs. 10:1305–1314. 2009.PubMed/NCBI
20.	Wilhelm SM, Carter C, Tang L, et al: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64:7099–7109. 2004. View Article : Google Scholar : PubMed/NCBI
21.	Dal Lago L, D’Hondt V and Awada A: Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors. Oncologist. 13:845–858. 2008.PubMed/NCBI
22.	Blumenschein GR Jr, Gatzemeier U, Fossella F, et al: Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J Clin Oncol. 27:4274–4280. 2009. View Article : Google Scholar : PubMed/NCBI
23.	Dy GK, Hillman SL, Rowland KM Jr, et al North Central Cancer Treatment Group Study N0326: A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer: North Central Cancer Treatment Group Study N0326. Cancer. 116:5686–5693. 2010. View Article : Google Scholar : PubMed/NCBI
24.	Carter CA, Chen C, Brink C, et al: Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma. Cancer Chemother Pharmacol. 59:183–195. 2007. View Article : Google Scholar : PubMed/NCBI
25.	Scagliotti G, Novello S, von Pawel J, et al: Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small cell lung cancer. J Clin Oncol. 28:1835–1842. 2010. View Article : Google Scholar : PubMed/NCBI
26.	Paz-Ares LG, Biesma B, Heigener D, et al: Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer. J Clin Oncol. 30:3084–3092. 2012. View Article : Google Scholar : PubMed/NCBI
27.	Plastaras JP, Kim SH, Liu YY, et al: Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation. Cancer Res. 67:9443–9454. 2007. View Article : Google Scholar : PubMed/NCBI
28.	Takezawa K, Okamoto I, Yonesaka K, Hatashita E, Yamada Y, Fukuoka M and Nakagawa K: Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells. Cancer Res. 69:6515–6521. 2009. View Article : Google Scholar : PubMed/NCBI
29.	Mahaffey CM, Davies AM, Lara PN Jr, et al: Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation. Clin Lung Cancer. 8:548–553. 2007. View Article : Google Scholar : PubMed/NCBI
30.	Cheng H, An SJ, Zhang XC, et al: In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell lines. Cancer Chemother Pharmacol. 67:637–646. 2011. View Article : Google Scholar : PubMed/NCBI
31.	Dougherty DW and Friedberg JW: Gemcitabine and other new cytotoxic drugs: will any find their way into primary therapy? Curr Hematol Malig Rep. 5:148–156. 2010. View Article : Google Scholar : PubMed/NCBI
32.	Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 65:55–63. 1983. View Article : Google Scholar : PubMed/NCBI
33.	Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55. 1984. View Article : Google Scholar : PubMed/NCBI
34.	Strumberg D, Clark JW, Awada A, et al: Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist. 12:426–437. 2007. View Article : Google Scholar : PubMed/NCBI
35.	Rajeswaran A, Trojan A, Burnand B and Giannelli M: Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of meta-static non-small cell lung carcinoma: a systematic review of randomized controlled trials. Lung Cancer. 59:1–11. 2008.
36.	Maemondo M: Timing the change of chemotherapy for non-small cell lung cancer. Gan To Kagaku Ryoho. 39:1316–1319. 2012.(in Japanese).
37.	Ayoola A, Barochia A, Belani K and Belani CP: Primary and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: an update. Cancer Invest. 30:433–446. 2012. View Article : Google Scholar : PubMed/NCBI
38.	Petrelli A and Giordano S: From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. Curr Med Chem. 15:422–432. 2008. View Article : Google Scholar : PubMed/NCBI
39.	Pasqualetti G, Ricciardi S, Mey V, Del Tacca M and Danesi R: Synergistic cytotoxicity, inhibition of signal transduction pathways and pharmacogenetics of sorafenib and gemcitabine in human NSCLC cell lines. Lung Cancer. 74:197–205. 2011. View Article : Google Scholar : PubMed/NCBI
40.	Zhang XH, Shin JY, Kim JO, Oh JE, Yoon SA, Jung CK and Kang JH: Synergistic antitumor efficacy of sequentially combined paclitaxel with sorafenib in vitro and in vivo NSCLC models harboring KRAS or BRAF mutations. Cancer Lett. 322:213–222. 2012. View Article : Google Scholar : PubMed/NCBI
41.	Ulivi P, Arienti C, Zoli W, et al: In vitro and in vivo antitumor efficacy of docetaxel and sorafenib combination in human pancreatic cancer cells. Curr Cancer Drug Targets. 10:600–610. 2010. View Article : Google Scholar : PubMed/NCBI
42.	Torres K and Horwitz SB: Mechanisms of taxol-induced cell death are concentration dependent. Cancer Res. 58:3620–3626. 1998.PubMed/NCBI
43.	Li QL, Gu FM, Wang Z, et al: Activation of PI3K/AKT and MAPK pathway through a PDGFRβ-dependent feedback loop is involved in rapamycin resistance in hepatocellular carcinoma. PLoS One. 7:e333792012.